TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 24-hour systolic ABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour diastolic ABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vo2MAX improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of matrix metalloproteinases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombin generation capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: recovery of neural function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FEV(1)‐AUC during the first 2 h post‐dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total score of the PROMPT-QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DRP outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incisor crowding relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resectability of localized bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of high quality embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: inpatient costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: patient time costs
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Ventricular fibrillation conversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular fibrillation termination rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concordance between WB‐MRI and BS in identifying bone metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Size of anastomotic opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anastomotic stenosis occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in PPG AUC0:00-4:00h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum PPG excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: impact on mood and confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-recognition of progress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: meeting of individual needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Adhesion force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TBS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraprocedural oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular disease/Heart failure hospitalization (CVD/HFH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart failure hospitalization (HFH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased BA concentrations post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased GLP-1 and PYY levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IVRTm improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E-decm improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E/Em improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: systemic exposure to MP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of MP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of implementing universal rapid HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of attempts needed to intubate the ileo-cecal valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall polyp detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adherence to treatment guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate of FAL in treating GI dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ba-PWV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: decrease in spasm score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection rate of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Need for SLN FS
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: u-KIM1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak concentrations of irGH and ifGH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: area under the curve (AUC) of irGH and ifGH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: time-point concentrations of irGH and ifGH (15-60 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Self-reported impulse control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-restraint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of fruits and vegetables selected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of fruits and vegetables wasted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri-implant bone preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: clinical peri-implant soft tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient hyperkalemia
Endpoint domain: Adverse events/effects
Primary endpoint: Mean urine sodium/potassium ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Beneficial effect of donepezil treatment on function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CPRS‐R:S total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum plasma concentrations (C(max)) of BIA 2‐005 and oxcarbazepine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance of BIA 2‐005
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lower esophageal sphincter tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Residual pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PPT values improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete akinesia 5 minutes after retrobulbar injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach complete anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independence (RS <= 2)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: No-emesis rates at 48 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No-nausea rates at 48 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue antiemetics at 48 h
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percentage change in plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiome richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for discriminating lung cancer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking cessation at the end of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization for cardiovascular causes
Endpoint domain: Mortality/survival
Primary endpoint: HbA1c correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of sum score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental QALY gain
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incremental mean per-patient NHS costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Death or myocardial re-infarction at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: concentration of spermatozoa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: snack food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satiety responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neophobia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: post-prandial lipemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neovascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Weight for Height Z-score (WHZ) > 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average weight gain (g/kg/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children not wasted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curves (AUCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal dilation of suprasecond intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TTDPM (Total Time to Decrease Pain Measurement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) improvement in patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recurrence of no-reflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of inflammatory lesions on brain MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in proliferation of interferon‐gamma‐producing, myelin‐reactive CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in titers of myelin‐specific autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Death due to rejection
Endpoint domain: Mortality/survival
Primary endpoint: Late mortality beyond 30 days after transplant
Endpoint domain: Mortality/survival
Primary endpoint: CGM glucose values in the target range (3.9-7.8 mmol/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose variability (CV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of perfusion abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brow elevation along the midpupillary line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superior palpebral crease elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in jowl surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of leiomyoma reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to pelvic floor muscle exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sedentary time on work days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in number of breaks/sedentary hour on work days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in light activity during work hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional disability improvement (HAQ DI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Oxidized LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin 6 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Identification of LIP and UIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marks in trauma questions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in skills stations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in problem-solving stations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed for union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life factors
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BUA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in pressure ulcer days (PUDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained eGFR <60 ml/min/1.73 m(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positive emotional experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Focused internalized attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain of insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain of removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea/hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: active external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: passive external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain relief with passive adduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relieving the discomfort of dry mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-body glucose counterregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response time to conflicts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arthritis Impact Measurement Scales‐2 pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice Handicap Index of functional subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of survey administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mental health status scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: General health status scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fewer bed days of care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Response rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: electrically evoked compound action potential thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: electrically evoked stapedial reflex thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improved functional scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved range of motion (flexion elevation, external rotation, internal rotation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25-foot walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yield of TBNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehospitalization for new or worsened congestive heart failure (CHF)
Endpoint domain: Mortality/survival
Primary endpoint: percentage duration of activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: median number of waves greater than 13 cm H2O
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visuospatial/executive subscale performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to clinically relevant reduction in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self‐rated Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in logMAR visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in area of choroidal neovascular membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVD incidence
Endpoint domain: Mortality/survival
Primary endpoint: serum lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: time to return to baseline QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to return to baseline PC scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average wrinkle grades reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of LSA branches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total LSA length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum erythropoietin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in soluble P-selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of platelets expressing P-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Theophylline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theophylline half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rectal compliance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal toleration volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving Normal Glucose Tolerance (NGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGT to DM conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CM symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: plasma sitosterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma campesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma lathosterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in scores on SCL-90-R, HAM-D, HAM-A, and State-Trait Anger Expression Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in high CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-care behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Conspicuity of renal structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes